GDF15 levels have been positively associated with the severity of fibrosis in patients with biopsy-proven NAFLD, indicating its potential as a biomarker for the progression of liver fibrosis (42). This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatotic liver disease.